HIGH RISK NEUROBLASTOMA

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on neuroblastoma cells. It is for children and young adults aged 1 to 21 whose cancer has come back or not responded to standard treatments. Participants first receive ch…

This study tests a bivalent vaccine (with an immune booster) plus an oral supplement called β-glucan in 94 children with high-risk neuroblastoma that is in complete remission. The goal is to see which schedule of β-glucan helps the vaccine produce stronger antibodies to keep the …

This early-stage trial tests a new treatment called GPC2 CAR T cells for children with advanced neuroblastoma or retinoblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and at…

This study tests a new treatment for children and young adults with high-risk neuroblastoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein called ALK found o…

This study tests a chemotherapy plan called N10 for children with high-risk neuroblastoma, a serious nerve cell cancer. The goal is to see if it works well and is safe enough to use as a first treatment. About 45 children under 19 with newly diagnosed high-risk neuroblastoma will…

This early-phase trial tests a new treatment for children with neuroblastoma that has come back or is hard to treat. The therapy uses the patient's own immune cells, modified to recognize and attack cancer cells carrying a protein called PHOX2B. The main goal is to find a safe do…

This study tests whether adding an antibody called hu14.18K322A to standard chemotherapy can better shrink or eliminate tumors in children and teens with high-risk neuroblastoma, a rare and aggressive nerve cancer. About 144 participants aged 18 months to under 18 years will rece…

This study is for children newly diagnosed with high-risk neuroblastoma, a serious nerve cell cancer. Researchers are adding a drug called naxitamab to the usual chemotherapy to see if it helps more tumors shrink or disappear. About 93 children will take part, and the goal is to …

This study looks at whether adding a special support program (called Pediatric RISE) to usual care can reduce financial and material hardships for low-income families of children with high-risk neuroblastoma. About 84 families will be randomly assigned to get either usual care al…